Seaport Therapeutics
Seaport Therapeutics is seeking a Program Leader for its neuropsychiatric medicines program, overseeing clinical development and commercialization efforts for a Phase 2b study with plans for future regulatory filings and market activities. The role is highly strategic, integrating scientific, clinical, operational, and commercial perspectives to ensure successful program execution.
Seaport Therapeutics is a biotechnology company developing novel neuropsychiatric medicines. The company applies its Glyph platform to advance potentially best-in-class therapeutics designed to improve efficacy and tolerability for patients with depression, anxiety, and other neuropsychiatric disorders.
Seaport Therapeutics and Monash Institute of Pharmaceutical Sciences Awarded up to $15 Million from ARPA‑H to Advance Seaport’s GlyphCele™, the First Oral Therapeutic Designed to Restore Gut Lymphatic Function
2 weeks ago
Seaport Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
Jan 5, 2026
Seaport Therapeutics Presents New Meta-Analysis Examining the Impact of Clinical Trial Design Factors on Placebo Response in Generalized Anxiety Disorder Trials
3 weeks ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Seaport Therapeutics.
111% above the average for this role
Director, Biostatistics
Definium Therapeutics
Clinical Research Physician - Oncology
Eli Lilly and Company
Global Medical Development (GMD) Manager
Sandoz
Senior Clinical Scientist
AbCellera
Director, Product Communications
Definium Therapeutics
Associate Medical Director or Medical Director
Iambic Therapeutics